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Abstract 
BACKGROUND: Chemical modifications such as PEG, polyamine and radiolabeling on 
proteins can alter their pharmacokinetic behaviour and their blood-brain barrier (BBB) 
transport characteristics. NOTA, i.e. 1,4,7-triazacyclononane-1,4,7-triacetic acid, is a 
bifunctional chelating agent that has attracted the interest of the scientific community for its 
high complexation constant with metals like gallium. Until now, the comparative BBB 
transport characteristics of NOTA-modified proteins versus unmodified proteins are not yet 
described.  
METHODS: Somatropin (i.e. recombinant human growth hormone), NOTA-conjugated 
somatropin and gallium-labelled NOTA-conjugated somatropin were investigated for their 
brain penetration characteristics (multiple time regression and capillary depletion) in an in 
vivo mice model to determine the blood-brain transfer properties.  
RESULTS: The three compounds showed comparable initial brain influx, with Kin = 0.38 ± 
0.14 µL/(g×min), 0.36 ± 0.16 µL/(g×min) and 0.28 ± 0.18 µL/(g×min), respectively. 
Capillary depletion indicated that more than 80% of the influxed compounds reached the 
brain parenchyma. All three compounds were in vivo stable in serum and brain during the 
time frame of the experiments.  
CONCLUSIONS: Our results show that modification of NOTA as well as gallium chelation 
onto proteins, in casu somatropin, does not lead to a significantly changed pharmacokinetic 
profile at the blood-brain barrier. 
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Introduction 
Protein biopharmaceuticals have marched their way into the medicine landscape since the 
approval of the first recombinant protein insulin, Humilin®, in 1982. Since then, further 
research on protein modifications, either engineered (e.g. polyethylene glycol (PEG)-ylation, 
drug-conjugation, radiolabeling), originating from the expression host (e.g. post-translational 
modifications (PTM)) or resulting from the manufacturing process, have gained the interest 
by the biopharmaceutical community. Chemical modifications change the physicochemical 
properties, hence, alter the pharmacologic activity and pharmacokinetic profile of the protein 
under investigation. For example, changed elimination via a combination of changed 
proteolysis, renal ultrafiltration, liver clearance and/or starvation by the immune system, as 
well as specific interaction and/or accumulation within tissues is observed for PEGylations.1, 2 
Also modifications of proteins with bifunctional chelating agents (BFCA) such as 1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA) allow the incorporation/chelation of 
radiometals (e.g. 68Ga and 67Cu) and conjugation onto a targeting ligand via a linker, thereby 
opening the way for theranostic applications.3-6 
Conjugating moieties typically target functional groups on proteins such as amine, carboxyl 
and sulfhydryl, which are generally present in multiple copies on the protein and which can 
lead to complex product outcomes.3, 7 The conjugate-targeting ligand ratio or substitution 
degree can influence the target-binding functionalities, the in vivo stability, clearance and 
biodistribution.8-10  
In general, the ability to freely cross the blood-brain barrier (BBB) depends on the 
physicochemical properties (e.g. molecular size, charge and lipophilicity) and is often a closed 
route for proteins. However, chemical modifications on proteins such as polyamine 
modifications have demonstrated a higher permeability at the BBB compared to their 
unmodified counterparts.11-13 
In this study, the model protein of interest is somatropin (i.e. a recombinant human growth 
hormone (rhGH), INN) modified with 2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-
1,4,7-triacetic acid (p-SCN-Bn-NOTA) moieties.7 Currently, evidence points to the 
involvement of growth hormone (GH) and its receptor (GHR) on tumour progression.14-22 The 
GHR internalizes after signal transduction and nuclear GHR-localization is associated with 
different cancers, which makes GHR an interesting target to further explore for theranostic 
purposes.23-26 
  
Previously, speculations were made on the passage of somatropin over the BBB, because 
expression of the GHR has been demonstrated in the central nervous system (CNS) (amongst 
others choroid plexus, hypothalamus, pituitary, hippocampus and putamen 27-29) and 
administration of somatropin has established positive effects on the CNS (reviewed in 30, 31). 
Pan et al. demonstrated that rat and mouse GH are characterized with a significant blood-to-
brain influx transfer constant in rats.32 However, as chemical modifications of proteins, such 
as NOTA-conjugation, are often required in radiopharmaceutical medicines, an unresolved 
question was if those modifications influence the BBB transport and if they do show a 
different behaviour once complexed with a metal? To our knowledge, the comparative BBB 
transport characteristics of NOTA-modified proteins versus unmodified proteins are not yet 
reported. We investigate here the blood-brain barrier behaviour of NOTA-modified 
somatropin and gallium-chelated NOTA-modified somatropin as model compounds. 
 
Materials and methods 
Chemicals and reagents 
Zomacton® 4 mg (Ferring, somatropin Ph.Eur.) was obtained from Ghent University Hospital 
(Ghent, Belgium) and p-SCN-Bn-NOTA was purchased from Macrocyclics Inc. (Dallas, TX, 
USA). Bovine serum albumin (BSA) was obtained from Merck KGaA (Darmstadt, Germany). 
Dermorphin was synthesised at Hanhong (Shanghai, China). Ultrapure water was purified 
with a quality of 18.2 MΩ.cm using an Arium 611 purification system (Sartorius, Göttingen, 
Germany). For the purification of gallium-chelated NOTA-somatropins, the PD-10 sephadex 
G-25M column was obtained from GE healthcare (Diegem, Belgium). The Pierce® Pre-
Coated iodination tubes, iodine-125 carrier free radionuclide and argent filters used during 
radiolabeling of the compounds were purchased at Thermo Scientific (Erembodegem, 
Belgium), Perkin Elmer (Zaventem, Belgium) and Sterlitech (Kent, USA), respectively. The 
other chemicals and reagents were purchased at Sigma Aldrich (Diegem, Belgium): gallium 
trichloride, potassium chloride, calcium dichloride dihydrate, sodium lactate, magnesium 
sulphate, hydrated sodium dihydrogen phosphate, urethane, D-glucose, sodium hydroxide, 
trichloroacetic acid (TCA), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 
protease inhibitor cocktail; VWR (Leuven, Belgium): disodium hydrogen phosphate dihydrate 
and sodium chloride; and AppliChem GmbH (Darmstadt, Germany): dextran. Gradient grade 
acetonitrile and trifluoroacetic acid (TFA) came from Fisher Scientific (Erembodegem, 
Belgium). 
  
 
Animals 
The animal experiments were performed according to the Ethical Committee principles of 
laboratory animal welfare and approved by our institute (Ghent University, Faculty of 
Veterinary Medicine, Prof. Dr. K. Hermans, approval number EC2014/128, approved on 17th 
of November 2014). All efforts were made to minimize suffering. Female, Institute for Cancer 
Research, Caesarean Derived-1 (ICR-CD-1) mice of age 7-10 weeks and weighing 29-32 g, 
were obtained from Envigo RMS B.V. (Venray, Netherlands).  
 
Compounds under investigation 
The BBB behaviour of somatropin, 10:1 NOTA:somatropin and gallium-chelated 10:1 
NOTA:somatropin (or Ga-10:1 NOTA:somatropin) was investigated. The synthesis and 
analytical characterization of 10:1 NOTA:somatropin is described in Bracke et al.7 The 
NOTA-moieties of 10:1 NOTA:somatropin were chelated with gallium by incubating 1 mg of 
10:1 NOTA:somatropin, dissolved in 500 µL ammonium acetate buffer (0.1 M pH 5.5, 
supplemented with 0.2 mM acetylaceton) together with 1500 µL of a 571 µM gallium 
solution (285 µL of a 4 mM GaCl3 bulk solution in 0.1 M HCl added to 570 µL 0.05 M 
NaOH and 1140 µL ammonium acetate buffer) and incubated for 1 h at 37°C in the dark, 
while shaking at 750 rpm. The sample was loaded onto a PD-10 column (previously rinsed 
using 25 mL of 25 mM phosphate buffer, pH 7.4) and eluted using 2 mL of a 25 mM 
phosphate buffer, pH 7.4. BSA and dermorphin were included as negative and positive 
controls in the MTR study, both dissolved in 25 mM phosphate buffer pH 7. Both control 
compounds are specific for their BBB-influx purpose, while in other experiments like CD or 
stability, these 2 controls are of no relevance, and assurance of the experimental results are 
obtained by good laboratory practices. 
 
Radiolabeling of the compounds 
The radiolabeling of the compounds was performed using the Iodogen method.33-35 In brief, 
the Pierce® Pre-Coated iodination tubes were pre-rinsed with 1 mL 25 mM phosphate buffer 
pH 7.4. Then, 50 μL of a 1.1 mM NaI in 500 mM phosphate buffer pH 7.4 and 15 μL Na125I 
(eq. 1 mCi) were added in the Iodogen tubes, mixed and incubated for six minutes at room 
temperature. The iodonium solution was transferred to a tube containing 50 µg protein or 
peptide and the reaction was proceeded for six minutes at room temperature. Purification (i.e. 
  
separation of the unbound iodonium vs. radiolabeled protein) was performed by adding 500 
µL 25 mM phosphate buffer pH 7.4 to the reaction mixture, followed by filtration through an 
argent filter. The appropriate protein and peptide concentrations (i.e. 30 000 cpm/µL for 
multiple-time regression analysis (MTR) and 10 000 cpm/µL for capillary depletion (CD)) 
were prepared using Lactated Ringer’s solution containing 1% of BSA (LR/BSA).  
 
Multiple-time regression analysis 
After anesthetization of the ICR-CD-1 mice by intraperitoneal injection with a 40% (m/V) 
urethane solution (3 g/kg), the jugular internalis vein and carotid artery were isolated and 200 
µL of the compound solution was injected into the jugular vein. Blood was collected from the 
carotid artery at regular time points after injection (1, 1, 3, 5, 10, 12.5, 15 and 15 min; one 
time point per mouse and a total of eight mice per compound, which is in accordance to 
previous MTR designs reported by our group), followed by immediate decapitation.35-39 This 
was done independently for each of the compounds (somatropin, 10:1 NOTA:somatropin, Ga-
10:1 NOTA:somatropin and both controls). Next, the brains were collected and weighed, and 
serum was prepared by centrifugation of the blood at 10 000 g for 15 min at 21°C. 
Radioactivity of the blood, serum and brain was measured using a Wallac Wizard automatic 
γ-counter (Perkin Elmer, Shelton, CT, USA). 
In order to determine the BBB permeability of the compounds, the ratio of the brain and 
serum concentration (µL/g) was plotted versus the exposure time (Θ).40 The exposure time is 
calculated as the integral of the concentration of compounds in the serum (Cp) from start (t=0 
min) to the experimental time T (i.e. the area under the curve), divided by the concentration of 
compound in serum at time T:  (1). Working with the exposure time instead of 
the experimental time, allows to correct for the serum radioactivity decay over time and 
represents the theoretical steady state serum concentration level. A linear model of the blood-
brain transfer was used to derive the influx parameters as elaborated by Gjedde and Patlak: 
           (2) 
where Am(t) is the amount of radioactivity in brain (cpm/g) at time T, Cp(t) is the amount of 
radioactivity in serum (cpm/µL) at time T, Kin is the influx rate constant and Vi is the initial 
volume of distribution.41-43 
  
The elimination rate constant (ke) and serum half-life (T1/2) were calculated from the serum-
concentration time curves, based on a one compartment model:  (3) and 
 (4).44 
 
Capillary depletion 
The CD method was performed to distinguish the distribution of the compounds (somatropin, 
10:1 NOTA:somatropin and Ga-10:1 NOTA:somatropin) between brain parenchyma and 
cerebral capillaries.35-39, 45, 46 Each compound was injected in two anesthetized mice as 
described in the MTR section. Before decapitation at 10 minutes post injection, blood was 
collected from the abdominal aorta followed by cardiac perfusion with 20 mL LR buffer, after 
clamping the aorta and severing the jugular veins. Brains were collected and radioactivity was 
measured, followed by homogenisation of the brain in 0.7 mL ice cold capillary buffer (10 
mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl2, 1 mM MgSO4, 1 mM NaH2PO4 and 
10 mM D-glucose, pH 7.4) and 1.7 mL of ice cold 26% m/V dextran solution in capillary 
buffer. The resulting homogenate was weighed and centrifuged at 4500 g for 30 min at 4°C. 
The pellet (i.e. capillaries) and supernatant (i.e. parenchyma and fat tissue) were weighed and 
measured in the γ-counter. Serum was prepared from the collected blood by centrifugation at 
10 000 g for 15 minutes at 21°C and measured in the γ-counter as well. The compartmental 
distribution was calculated as follows: 
   (5) 
 
Tissue distribution after IV injection 
From the 15 minutes time points from the MTR study, tissues (spleen, kidney, liver, lungs, 
heart and serum) were collected after decapitation, weighed (Wtissue) and radioactivity was 
measured in the γ-counter (Atissue). The percentage of injected dose (i.d.) for each tissue was 
calculated as follows, with AIV injected the measured radioactivity of the MTR stock solution 
and Wmouse the weight of the injected mouse: 
        (6) 
 
In vivo stability 
  
The in vivo stability evaluation was performed according to Pan et al.32 Proteins in serum 
samples from the MTR study were precipitated by addition of 15% TCA. Supernatant and 
pellet, corresponding to degradation fragments and intact protein, respectively, were separated 
by a 30 minutes centrifugation step at 4000 g. The brains collected during the MTR study, 
were homogenized in 1 mL of ice cold LR/BSA solution and 10 µL protease inhibitor 
cocktail. This mixture was centrifuged for 2 minutes at 4000 g and 500 µL of the supernatant 
was transferred into a new tube. Intact protein was precipitated by addition of 15% TCA, 
vortexed and separated from supernatant by a 30 min centrifugation step at 4000 g and 4°C. 
Radioactivity (A) of the supernatant and the pellet of brains and serum were measured in the 
γ-counter. The percentage intact protein was calculated as follows 
.7 For the kinetic evaluation, the 
percentage of intact protein at 1 minute post injection was taken as a 100% reference. 
Assuming first-order kinetics, a linear regression analysis of the ln(percentage intact protein) 
versus the post-injection time was performed to calculate the half-lives of the somatropins in 
mouse serum and brain. 
 
Statistics 
Regression analysis was performed using the least squares method. Regression lines of the 
MTR study were statistically compared using the Prism 5 software (Graphpad, La Jolla, 
USA). Slopes were not statistically significantly different if the P-value was greater than 0.05. 
 
Results 
Blood-to-brain transport kinetics  
In Figure 1 and Table 1, the MTR results of somatropin, 10:1 NOTA:somatropin, Ga-10:1 
NOTA:somatropin and both controls are given. The investigated somatropins all showed a 
significant influx with a Kin between 0.28 and 0.38 µL/(g×min) and similar initial distribution 
volumes, i.e. Vi between 17.12 and 22.11 µL/g, which were not significantly different from 
each other (Figure 1A). The Vi resembles the effective vascular brain distribution volume of 
the protein including the protein in the vascular space and bound to or accumulated in 
capillary endothelial cells. Based on the peptide classification according to their BBB influx, 
somatropin, 10:1 NOTA:somatropin and Ga-10:1 NOTA:somatropin have a low influx.47 
The data of BSA and dermorphin (Figure 1B) demonstrated the validity of the results and 
were comparable to previous influx data published by our group or found in literature: 
  
iodinated BSA shows brain Kin values of around 0.13 µL/g×min and brain Vi of around 
15 µL/g, which is considered as almost absent, and thus a class 1 compound according to 
Stalmans et al.; dermorphin is considered a positive control which shows a significant but 
relatively low brain influx (class 2 according to Stalmans et al.). 35-39, 47, 48 The combination of 
both controls serves as a system suitability quality test of the MTR-experiment: a clear 
difference between the brain influxes of both compounds should be observed to assure this in-
vivo experiment.  
Overall, the somatropins had a higher Kin and Vi value than the negative control BSA. 
 
Figure 1: Multiple time regression curves of the exposure time versus the ratio of the brain and serum activity. A: Somatropin, 10:1 
NOTA:somatropin and Ga-10:1 NOTA:somatropin. B: BSA and dermorphin, negative and positive controls respectively. Data were 
fitted using the linear Gjedde-Patlak model.  
 
Table 1: Overview of the multiple time regression results, with the 65% confidence interval indicated. 
Parameter Somatropin 
10:1 
NOTA:somatropin 
Ga-10:1 
NOTA:somatropin 
BSA Dermorphin 
Kin (µl/(g × min)) 0.38 ± 0.14 0.36 ± 0.16 0.28 ± 0.18 0.13 ± 0.05 0.48 ± 0.09 
Vi (µl/g) 17.12 ± 2.60 20.28 ± 2.80 22.11 ± 3.05 15.12  ± 0.69 18.24 ± 1.64 
Kin = unidirectional influx rate 
Vi = initial brain distribution volume 
 
The radioactivity in serum (corrected for injected dose) was plotted versus time (Figure 2) 
and the serum half-lives were estimated. The serum half-lives were in the same order of 
magnitude, i.e. between 7 and 10 min, for somatropin, NOTA-modified somatropin and 
gallium-labeled NOTA-modified somatropin (Table 2). 
  
 
Figure 2: Serum concentrations of somatropin, 10:1 NOTA:somatropin and Ga-10:1 NOTA:somatropin in function of time (min), as 
obtained during the MTR experiments. Data were fitted using a one compartment model (dashed lines). 
 
Table 2: Serum radioactivity time curve parameters. 
Parameter Somatropin 10:1 NOTA:somatropin Ga-10:1 NOTA:somatropin 
ke (min-1) 0.100 0.097 0.072 
c0 20883 16245 12617 
T1/2 (min) 6.911 7.138 9.673 
R2 0.859 0.795 0.899 
Parameters are based on a one compartment model 
Capillary depletion 
The compartmental distribution of the radiolabelled compounds in the brain was estimated 
using the capillary depletion method. In the CD method, a cardiac perfusion step washes out 
the residual radioactivity in the brain vasculature, thereby allowing to distinguish between 
compounds that have reached the brain parenchyma and compounds that are trapped in the 
capillaries. The parenchymal fraction amounted 80% for somatropin, which is comparable to 
previous obtained results and confirms the validity of the method.32 Parenchymal fractions of 
82% and 81% were obtained for 10:1 NOTA:somatropin and Ga-10:1 NOTA:somatropin, 
respectively (Figure 3). This indicates that only about 20% of the measured radioactivity was 
trapped in the brain capillaries. 
  
 
Figure 3: Capillary depletion compartmental distribution results normalized for brain weight (mean absolute amounts in μL/g ± 
SEM, n=2), showing a very high brain parenchymal penetration for all investigated compounds. Atissue and Aserum are the measured 
activities in the concerned tissue and serum, respectively.  
 
Tissue distribution 
After 15 minutes post injection, both somatropin and 10:1 NOTA:somatropin were mainly 
found in serum, kidney and liver. Once gallium is complexed in 10:1 NOTA:somatropin, the 
compound was mainly distributed in serum (Figure 4). The tissue distribution of the positive 
and negative control corresponded well with previously obtained research results.35, 37-39 
 
Figure 4: Relative tissue distribution at 15 minutes post injection, expressed as the percentage of the injected dose (ID) (mean ± 
SEM, n=2). From left to right: brain, spleen, kidney, lungs, heart, liver and serum. A 100% ID indicates that the concentration of the 
compound within the tissue is the same as the mean concentration over the entire animal (i.e. homogeneous distribution).  
 
  
In vivo stability 
The in vivo stability was evaluated according to the TCA precipitation method of Pan et al.32 
Using this method, a separation is made between intact protein (precipitate) and degradation 
products (e.g. metabolites (peptides) or free iodine as a result of deiodination; supernatant). A 
first-order kinetic is assumed in the calculation of the rate constant (k) and related half-life 
(Figure 5). The calculated metabolic half-lives were for all three compounds between 17 and 
30 min in serum and brain.  
 
Figure 5: First-order kinetics of the in vivo stability in serum (left) and brains (right). Black: somatropin, gray: 10:1 
NOTA:somatropin and blue: Ga-10:1 NOTA:somatropin. Fitting results and calculated half-lives are shown in the insets. 
 
Discussion 
The effect of NOTA-conjugation on the BBB transport characteristics of proteins, has not yet 
been described. The BBB is a unique, selective interface formed by the tight junctions 
between the endothelial cells that line the cerebral capillaries, as well as the metabolic barrier 
and the specific transport systems.49, 50 Molecules that readily pass the BBB under normal 
conditions are traditionally explicitly small and lipophilic; however, saturable transport 
systems are described for different proteins, e.g. interleukins, tumour necrosis factor α and 
interferons.46, 51-57 This means that molecules can diffuse passively through the BBB (mainly 
small, lipophilic molecules) or make use of a carrier- or receptor-mediated transport system as 
also for peptides and proteins.58 Receptor-mediated transport systems are now strategies used 
for the transport of protein therapeutics across the BBB, e.g. bispecific antibodies with 
binding to the transferrin receptor (TfR).59 Some proteins however, do not pass this BBB and 
are here used as vascular markers, characterized by a negligible vascular brain distribution 
volume (on average 8.0 µL/g).41, 60 BSA is a known protein vascular marker, but 
radioiodination of BSA has been demonstrated to show some nonspecific binding to cerebral 
capillaries in comparison to the tritiated form, explaining the observed brain influx and higher 
  
initial brain distribution volume (Vi = 15 µL/g).
61 In fact, molecular modifications on 
substances is one of the nine mechanisms influencing brain penetration of compounds, but 
unfortunately, the pharmacokinetic outcome is often difficult to predict.62 As exemplified by 
Banks et al., PEGylations can both enhance and reduce the BBB permeation. Also glucose 
modifications enhanced the BBB penetration, but these modifications did not target the 
expected glucose transporter GLUT1.62-63 Therefore, the inclusion of a BBB permeability 
study is recommended to investigate the potential of drugs and their modification moieties to 
target the CNS, with (i) intentional passage e.g. for treatment of CNS diseases or (ii) 
unintentional passage e.g. to estimate non-selective tissue distribution in CNS during ligand-
targeted radiopharmaceutical development.64 
Rat GH was previously characterized by a low brain influx (Kin of 0.23 and 0.32 µL/(g×min) 
in mice and rat, respectively) demonstrated that a recombinant, human GH (somatropin) with 
cross-species reactivity (i.e. human ligand binds mouse receptor), has a similar brain influx of 
0.38 ± 0.14 µL/(g×min) in the mouse model.32, 65, 66 The 10:1 NOTA:somatropin sample 
contains a mixture of products with different NOTA-substitution degrees and positional 
isomers.7 No altered functional receptor binding potency was demonstrated for 10:1 
NOTA:somatropin and Ga-10:1 NOTA:somatropin compared to unmodified somatropin.67 In 
this study, we could not demonstrate a significantly different BBB kinetic transport behaviour 
for these three compounds. Moreover, the compartmental distribution in the brain parenchyma 
and brain capillaries was also similar for the three compounds, with an estimated higher 
parenchymal localisation (≥ 80%). From our results, we can conclude that for 10:1 
NOTA:somatropin with or without gallium chelation, there was no significantly different 
BBB behaviour compared to unmodified somatropin.  
The serum half-lives for somatropin, 10:1 NOTA:somatropin and Ga-10:1 NOTA:somatropin 
were calculated to be 6.9, 7.1 and 9.7 minutes, respectively. As seen from the tissue 
distribution after 15 minutes post injection, somatropin and 10:1 NOTA:somatropin are 
highly distributed in serum, liver and kidney. The kidney is the main clearance site for GH, 
the liver is the main target site for GH action with GHR expression; and the extracellular part 
of the GHR, known as the growth hormone binding protein (GHBp), circulates separately in 
the blood at nanomolar concentrations, where it will bind with a substantial part of plasma 
GH (40-50%).68-73 Binding to GHBp can positively influence the serum half-life. The Ga-
chelated 10:1 NOTA:somatropin showed a different tissue distribution profile: significantly 
high serum levels were found and no preferential tissue uptake was observed. 
  
Next to the tissue distribution, also the in vivo metabolic stability was evaluated which can 
contribute to the serum half-lives. All three compounds (somatropin, 10:1 NOTA:somatropin 
and Ga-10:1 NOTA:somatropin) were relatively stable during the 15 minutes time period of 
the MTR experiment with metabolic half-lives between 17-30 minutes in serum and brain. 
Because the compounds were labeled with 125I and the TCA precipitation method was used 
(precipitate vs. soluble radioactivity), no direct conclusions could be made for the in vivo 
stability of the lysine-isothiocyanate(linker)-NOTA conjugation and the Ga-NOTA chelation. 
However, isothiocyanates are amine-reactive groups, form thiourea bonds onto lysine residues 
and are more stable than other amine-reactive linkers such as N-hydroxysuccinimide (NHS) 
esters.4 The Ga-NOTA chelate is characterized with a high complexation constant (Log(KML) 
= 31.0) and remains intact in nitric acid over a period of 6 months, indicative for a high 
stability.74-75 Indeed, gallium-p-SCN-Bn-NOTA-peptide conjugates have been reported to be 
stable in serum for >90% over 4 h, in the presence of apotransferrin.76  
GH has been related to effects in the CNS such as sleep, mood, cognitive function, memory 
but also on neuroprotection, apetite and feeding behaviour.30, 31, 77 The expression of the GHR 
in the different brain regions support these functional observations. At this moment, data on 
GH mechanisms on brain function remains limited and has to be further elucidated.78 The 
NOTA-modified somatropins offer opportunities not only for targeting of GHR-
overexpressing tumours as diagnostic and/or therapeutic agent, but also for imaging toward 
more fundamental, mechanistic research in the brain. 
 
Conclusions  
The BBB transport properties of somatropin after NOTA-conjugation and gallium chelation 
were investigated. Somatropin, 10:1 NOTA:somatropin and Ga-10:1 NOTA:somatropin all 
showed a low brain influx rate in the in vivo mice model, which were not significantly 
different from each other. In comparison to somatropin and 10:1 NOTA:somatropin, both 
having a pronounced tissue distribution to liver, kidney and serum, Ga-10:1 
NOTA:somatropin showed a somewhat different tissue distribution profile with a high serum 
level and no preferential tissue distribution. The compounds had a relatively high in vivo 
metabolic stability during the timeframe of the study (T1/2 between 17-30 minutes). Our 
results thus indicate that NOTA-modification, including gallium chelation, onto a protein 
characterized with a low brain influx, does not lead to significantly altered pharmacokinetic 
profile at the blood-brain barrier. 
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Table 1: Overview of the multiple time regression results, with the 65% confidence interval 
indicated. 
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Figure 1: Multiple time regression curves of the exposure time versus the ratio of the brain 
and serum activity. A: Somatropin, 10:1 NOTA:somatropin and Ga-10:1 NOTA:somatropin. 
B: BSA and dermorphin, negative and positive controls respectively. Data were fitted using 
the linear Gjedde-Patlak model.  
Figure 2: Serum concentrations of somatropin, 10:1 NOTA:somatropin and Ga-10:1 
NOTA:somatropin in function of time (min), as obtained during the MTR experiments. Data 
were fitted using a one compartment model (dashed lines). 
Figure 3: Capillary depletion compartmental distribution results normalized for brain weight 
(mean absolute amounts in μl/g ±SEM, n=2), showing a very high brain parenchymal 
penetration for all investigated compounds. Atissue and Aserum are the measured activities in the 
concerned tissue and serum, respectively. 
Figure 4: Relative tissue distribution at 15 minutes post injection, expressed as the percentage 
of the injected dose (ID) (mean ± SEM, n=2). From left to right: brain, spleen, kidney, lungs, 
heart, liver and serum. A 100% ID indicates that the concentration of the compound within 
the tissue is the same as the mean concentration over the entire animal (i.e. homogeneous 
distribution).  
Figure 5: First-order kinetics of the in vivo stability in serum (left) and brains (right). Black: 
somatropin, gray: 10:1 NOTA:somatropin and blue: Ga-10:1 NOTA:somatropin. Fitting 
results and calculated half-lives are shown in the insets. 
 
 
